Isoptin Retard

Verapamil Hydrochloride, the active ingredient in Isoptin Retard, is a calcium channel blocker presented as an oral extended‑release tablet for oral use. It is employed to manage high blood pressure, chest pain from angina, and certain cardiac rhythm disorders in adult patients.

GNH USA supplies Isoptin Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution in multiple jurisdictions, including compliance with EU GMP guidelines.

Isoptin Retard, a calcium channel blocker, is used in cardiovascular conditions that involve elevated vascular tone or abnormal cardiac conduction.

Hypertension: lowers systemic blood pressure by relaxing arterial smooth muscle. Angina pectoris: reduces myocardial oxygen demand and improves coronary blood flow. Cardiac arrhythmias (e.g., supraventricular tachycardia): slows atrioventricular nodal conduction to control heart rate.

Verapamil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate head pain. - Peripheral edema: swelling of ankles or feet. - Constipation: reduced bowel motility. - Dizziness or light‑headedness: due to blood‑pressure lowering.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate. - Heart block: impaired AV‑nodal conduction. - Severe hypotension: sudden drop in blood pressure.

When prescribing Isoptin Retard, clinicians should observe several precautionary measures to ensure patient safety.

Assess cardiac function: obtain baseline ECG and monitor for bradyarrhythmias. Review concomitant medications: avoid drugs that also depress AV conduction. Monitor blood pressure: adjust therapy if hypotension occurs. Use caution in hepatic impairment: dose may need adjustment. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Verapamil interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - Beta‑blockers (e.g., propranolol): risk of severe bradycardia and AV block. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic plasma concentrations.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, monitor for toxicity. - Statins metabolized by CYP3A4 (e.g., simvastatin): risk of myopathy, consider dose reduction. - Carbamazepine: may reduce verapamil effectiveness, monitor therapeutic response.